Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study


Kappos L., Gold R., Miller D. H. , MacManus D. G. , Havrdova E., Limmroth V., et al.

MULTIPLE SCLEROSIS JOURNAL, cilt.18, ss.314-321, 2012 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 18 Konu: 3
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1177/1352458511421054
  • Dergi Adı: MULTIPLE SCLEROSIS JOURNAL
  • Sayfa Sayısı: ss.314-321

Özet

Background: In a phase 2b study in patients with relapsing-remitting MS (RRMS), BG-12 240 mg three times daily significantly reduced the number of new gadolinium-enhanced (Gd+) lesions from weeks 12 to 24 (primary end point) by 69% compared with placebo.